Adoptive T cell therapy with HLA-A2 restricted NY-ESO-1/LAGE-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma and synovial cell sarcoma patients. This evidence concerns the gene CD8A and melanoma.